Medy Tox Inc

Medy Tox Inc maintains a strong liquidity position with a current ratio of 1.48, indicating the company can cover its short-term liabilities with its short-term assets. However, the company has a negative net cash position after subtracting total debt, which may pose a liquidity risk. The company's debt-to-equity ratio is 0.17, suggesting a relatively low level of leverage compared to industry norms. In terms of profitability, Medy Tox Inc has a return on equity (ROE) of 3.67% and a return on assets (ROA) of 2.85%. These figures are below the typical thresholds for high-performing pharmaceutical companies, indicating that the company is not generating strong returns relative to its equity and asset base. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may increase the company's exposure to market-specific risks. Medy Tox Inc's growth trajectory appears to be modest, with no significant revenue growth reported in the latest financial period. The company's capital expenditures are substantial, with a negative free cash flow of -8.68 billion KRW, indicating that the company is investing heavily in its operations. The company faces a medium liquidity risk, as highlighted in its risk assessment, and a low dilution risk. The negative net cash position after subtracting total debt is a key flag that may affect the company's financial stability. Recent events, including analyst estimates, suggest a mixed outlook for Medy Tox Inc. The mean price target is 113,000 KRW, with a median of 120,000 KRW, indicating a range of expectations among analysts. The mean recommendation is 3.00, which is a "Hold" rating, with no strong buy recommendations.